4.1. Conclusions
REMISSION
Based upon data from the SELECTION trial, filgotinib 200 mg resulted in short- and long-term improvements in generic and disease-specific HRQoL. Filgotinib 200 mg led to some patients achieving a stringent exploratory composite endpoint that may be associated with both improved HRQoL and histological remission. Further work is required to validate this exploratory endpoint.